Medicus Pharma’s subsidiary Antev Ltd. amended its licensing agreement with LifeArc, cutting the royalty rate on the Teverelix asset from roughly 4 % to 2 %. The change clarifies the royalty term on a country‑by‑country basis but does not alter the scope of the license, intellectual‑property rights, or Medicus’s development responsibilities.
Teverelix is a next‑generation, long‑acting gonadotropin‑releasing hormone antagonist designed for advanced prostate cancer patients who have high cardiovascular risk and for those experiencing acute urinary retention relapse. The drug targets a combined market opportunity of about $6 billion, and the royalty reduction improves the projected cash‑flow profile by lowering the cost of sales for any future partner.
For a clinical‑stage company that has yet to generate revenue, the economics of its flagship asset are critical. The lower royalty burden enhances Teverelix’s attractiveness to late‑stage developers and commercial partners, strengthening Medicus’s negotiating position and potentially accelerating the path to market. The company also continues to advance its SkinJect platform in Phase 2, but Teverelix remains the primary driver of future valuation.
Dr. Raza Bokhari, Medicus’s Executive Chairman and CEO, said the amendment “substantially improves the long‑term economic profile of Teverelix while preserving the strength and integrity of the underlying license. We believe the reduced royalty burden enhances Teverelix’s attractiveness for future partnering, especially for late‑stage development and commercialization.”
Investors responded positively to the announcement, citing the improved economics and partnership potential of Teverelix. The market reaction underscored the significance of the royalty reduction for Medicus’s future growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.